Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 130Breast Neoplasms 113Neoplasms 97Neoplasm Metastasis 78Melanoma 73Leukemia, Myeloid, Acute 69Colorectal Neoplasms 69Prostatic Neoplasms 60Multiple Myeloma 53Lung Neoplasms 52Ovarian Neoplasms 51Squamous Cell Carcinoma of Head and Neck 46Triple Negative Breast Neoplasms 42Recurrence 41Carcinoma, Renal Cell 39Carcinoma, Hepatocellular 39Myelodysplastic Syndromes 37Pancreatic Neoplasms 36Glioblastoma 35Brain Neoplasms 34Lymphoma 31Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Leukemia 29Lymphoma, Large B-Cell, Diffuse 28Head and Neck Neoplasms 28Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fibrocystic Breast Disease × 1 year × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡